Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
- License agreement centered around development of a single ADC program
- Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement
Amsterdam, The Netherlands, 9 January 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation (“MTPC”), the pharma arm of Mitsubishi Chemical Group (“MCG”).
